linjc16/ctgov huggingface dataset:
Association of Anticholinergic Burden With Onset of Delirium in Older Adults With Alzheimer Dementia:

Study Overview
=================
Brief Summary
-----------------
Drugs with anticholinergic properties are commonly prescribed to older persons despite growing evidence of their significant adverse effects. However, limited data are available concerning their contribution to time of onset of delirium. This study aimed to determine the potential association of higher anticholinergic burden to early-onset of delirium superimposed dementia in the older adult.

Official Title
-----------------
Association of Anticholinergic Burden With Onset of Delirium in Older Adults With Alzheimer Dementia: A Retrospective Cohort Study

Conditions
-----------------
Delirium, Anticholinergic Adverse Reaction, Alzheimer Disease

Intervention / Treatment
-----------------
* Drug: Anticholinergic burden


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 65 years and older and diagnosis or fellow-up of Alzhemier dementia in outpatient clinic. Exclusion Criteria: The patients with a history of other than Alzhemier dementia or neurodegenerative disease (epilepsy, multiple sclerosis, Parkinson disease, etc.), terminal illness (malignancy, advanced organ failure) were excluded.

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| early onset deliryum on dementia<br>It was earlier than The median time of onset of delirium superimposed dementia | Drug: Anticholinergic burden<br>* The anticholinergic burden (ACB) was assessed using the Anticholinergic Burden Scale. Higher ACB was described as equal or higher than 1.<br>|
| Delirium on dementia (normal)<br>It was equal or later than The median time of onset of delirium superimposed dementia | Drug: Anticholinergic burden<br>* The anticholinergic burden (ACB) was assessed using the Anticholinergic Burden Scale. Higher ACB was described as equal or higher than 1.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time onset of delirium superimposed dementia | First attack of delirium onset | 12 month |
Diagnosis of Acute Appendicitis, Ovary Torsion and Inflammation, and Testicular Torsion and Inflammation by Infrared Thermography

Study Overview
=================
Brief Summary
-----------------
Thermal, or infrared, energy is the part of electromagnetic radiation that an observer perceives as heat. Infrared thermography allows us to visualize temperature distribution of the human body and has been used in medical practice since the 1950s. In current study we would like to examine the ability of infrared thermography to detect acute appendicitis, ovary torsion and inflammation, and testicular torsion and inflammation.

Conditions
-----------------
Abdominal Pain, Testicle Pain

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: < 18 years old Exclusion Criteria: > 18 years old

Ages Eligible for Study
-----------------
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| children suffering from abdominal or testicle pain<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
children
Does Longitudinal Nursing Follow-up Improve Smoking Cessation in Patients Referred for COPD Screening

Study Overview
=================
Brief Summary
-----------------
a monocentric study to evaluate the efficacy of a longitudinal nursing follow up in smoking cessation in patients screened for Chronic obstructive pulmonary disease (COPD).

Detailed Description
-----------------
The challenges to limit the occurrence of COPD are early detection, the fight against smoking and smoking and addictions (e.g. Cannabis), as well as the fight against environmental exposures. we proposed to evaluate if a longitudinal nursing follow-up at 3 months, 6 months and one year, in patients coming to screening for COPD. Cessation of respiratory toxics is the most effective intervention in stopping the progression of COPD.

Official Title
-----------------
Does Longitudinal Nursing Follow-up Improve Smoking Cessation in Patients With Chronic Obstructive Pulmonary Disease (COPD) Screening

Conditions
-----------------
COPD, Nurse's Role

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Smoking patients screened for COPD between 35 years old 65 years old Read, write and understand the French language Patient affiliated to a social security system Written and signed informed consent Exclusion Criteria: Patients with a diagnosis of respiratory diseases Patients receiving inhaled respiratory therapy Persons unable to perform spirometry Pregnant women Refusal to participate in research Patient under guardianship, deprived of liberty, safeguard of justice

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of cigarettes or other toxic substances | per day | up to 1 year |
Validation of a New Standardized Clinical Anemia Evaluation Score Using a Hb Visual Scale in Nephrological Patients

Study Overview
=================
Brief Summary
-----------------
The clinical evaluation of anemia is usually done by examination of the palpebral conjontivae coloration. This appreciation remains crude and largely observer dependent, as no reference scale was successfully proposed,. A Hb visual scale allowing the assessment of the degree of clinical anemia has been developed. Its use has been validated so far in small patient groups in the following settings: blood donation, cardiac surgery, oncology and consultation of general practitioners. The objective of the present investigation is to validate the use of a Hb visual scale for the clinical evaluation of anemia in patients with kidney disease patients

Official Title
-----------------
Validation of a New Standardized Clinical Anemia Evaluation Score Using a Hb Visual Scale in Nephrological Patients

Conditions
-----------------
Anemia

Intervention / Treatment
-----------------
* Procedure: Estimation of Hb concentrations with the HemoHue card


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with chronich kidney disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Estimation of Hb concentrations with the HemoHue card|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of visual estimated Hb concentrations with measured Hb concentrations |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Anemia, Visual scale, nephrological patients, Anemia in nephrological patients
Registration and Fusion of Real-Time Ultrasound With CT for Lesion Localization and Characterization

Study Overview
=================
Brief Summary
-----------------
Acquire CT data and US and transducer position data (magnetic sensor system) of focal hepatic or renal lesions to serve as sample data sets for fusion algorithm development and subsequent optimization.

Detailed Description
-----------------
Acquire CT data and US and transducer position data (magnetic sensor system) of focal hepatic or renal lesions to serve as sample data sets for fusion algorithm development and subsequent optimization. Optimize image fusion algorithms for use in goal. Develop registration algorithms that result in maximal lesional overlap with a clinically relevant difference in an epicenter location of ≤ 2 cm for lesional identification and, ultimately ≤ 0.3 cm for interventional procedures.

Official Title
-----------------
Registration and Fusion of Real-Time Ultrasound With CT for Lesion Localization and Characterization

Conditions
-----------------
Kidney or Liver Tumors

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Focal lesion involving the liver or kidney bases on CT or MRI Imaging Liver lesion size >5 mm and <5 cm in diameter or renal lesion size is >5 mm and <4 cm in diameter Age >18 years old Patient has provided written informed consent Exclusion Criteria: Patient with cardiac pacemaker or defibrillator Pregnant or lactating woman Patient with severe IV contrast allergy (previous reaction to IV contrast not mitigated by appropriate premedication) Patient unable to give informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>patients with indeterminate kidney or liver lesions | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Primary Endpoints: Global Fiducial Registration Error (FRE) of real-time US and fused CT images, Target Registration Error (TRE) and distance between lesional epicenters of real-time US and fused CT images. |  | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Secondary Endpoint: Number of coregistration attempts to realize separation of lesional epicenters of real-time US and fused CT images of ≤2 cm and the number of attempts to realize a separation of ≤0.3 cm. |  | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Fusion, Ultrasound, Computed tomography
Patients With Chronic Pelvic Pain With Vaginal Microbiota

Study Overview
=================
Brief Summary
-----------------
Vaginal microorganisms play an important role in the occurrence and development of many diseases, such as persistent infection of high-risk human papillomavirus (HR-HPV) causing cervical intraepithelial neoplasia and cervical cancer, and the role of microorganisms in chronic prostatitis.

Official Title
-----------------
Chronic Pelvic Pain With Vaginal Microbiota in Gestational Women Without HPV Infection

Conditions
-----------------
Pelvic Pain

Intervention / Treatment
-----------------
* Other: Observation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Those are aged 20 to 45 years old, have vaginal intercourse more than 3 years, and aren't in menstrual, pregnancy or puerperium period. Exclusion Criteria: Those are aged more than 45 years old without HPV infection in the last one year, having no vaginal intercourse, and those can't cooperate the examiner. Women who are HIV or hepatitis B/C positive, have autoimmune disorders and systemic disease (like diabetes mellitus, hormone treatment diseases, severe liver and kidney dysfunction), or have severe mental illness and malignant tumors are also excluded. At the same time, all the participants should meet the following requirements: no vagina douching within last 2 days, no vaginal intercourse within last 3 days, no systemic application of antifungal agents or antibiotics or pessaries within last 14 days of sampling.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Male

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group A<br>Vaginal microbiota in gestation CPP women without HPV infection | Other: Observation<br>* The patients with the negative results of HPV infection, and assigned to different group according to the CPP manifestation.<br>|
| GroupB<br>Vaginal microbiota in gestation women without CPP and HPV infection | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Vaginal microbiota difference | Vaginal microbiota difference between the women with or without CPP, and all the cases are cervical HPV negative. | one year |
Usefulness of Acupuncture in Cancer Pain and Quality of Life

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the effects of acupuncture on aspects of health including pain, energy level, sleep quality, activities of daily living and appetite.

Detailed Description
-----------------
After receiving permission from the attending physician each study participant who meets the inclusion criteria will then undergo a physical examination and fill out several questionnaires. Each participant will undergo one to three treatments per week for a period of eight weeks. There will be one follow-up visit on the twelfth week. Participation in this study is free of charge, including all exams, treatment and informational material.

Official Title
-----------------
Acupuncture Case Series: Cancer Pain and Quality of Life

Conditions
-----------------
Cancer, Pain

Intervention / Treatment
-----------------
* Device: Acupuncture


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Confirmed diagnosis of cancer by an MD/oncologist Age of 18 or older Baseline pain score of 3 or above on 0-10 rating scale In the evaluation of the treating physician or medically-qualified investigator, the patient's pain syndrome is the result of underlying cancer or cancer treatment Being ambulatory Permission from the treating physician (MD/oncologist) Platelet count of 50,000 or greater Exclusion Criteria: Acupuncture treatment in past four weeks Neutropenia defined as ANC (absolute neutrophil count) < 1000/ml Inability to obtain permission from the treating physician Unwillingness to sign informed consent form Involvement in litigation Simultaneous infection with HIV or Hepatitis C virus Unable to present for follow up

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Single arm<br>Acupuncture treatment | Device: Acupuncture<br>* Acupuncture treatment twice a day for eight weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| EORTC QLQ-30 Quality of Life Questionnaire for Cancer Patients |  | Every two weeks, 0, 2, 4, 6, 8 and 12 | 
| Visual Analogue Scale |  | Every two weeks, 0,2,4,6,8, and 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| BDI Psychological Assessment |  | Every two weeks, 0, 2, 4, 6, 8 and 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cancer, Acupuncture, Cancer Pain, Quality of life
Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy

Study Overview
=================
Brief Summary
-----------------
Prophylactic use of Filgrastim SD/01 for patients with Hodgkin's lymphoma receiving ABVD chemotherapy.

Official Title
-----------------
Prophylactic Use of Filgrastim SD/01 In Patients With Hodgkin's Disease Receiving ABVD Chemotherapy

Conditions
-----------------
Hodgkin Disease

Intervention / Treatment
-----------------
* Drug: Filgrastim SD/01
* Drug: Adriamycin
* Drug: Bleomycin
* Drug: Vinblastine
* Drug: DTIC


Participation Criteria
=================
Eligibility Criteria
-----------------
INCLUSION: Previously untreated Hodgkin's disease patients who are scheduled to receive standard ABVD chemo. Histologically proven diagnosis of Hodgkin's disease of any type. Bidimensionally measurable disease. Signed informed consent. Age >/= 16 yrs. Adequate bone marrow reserve (ANC>1000/uL, Platelet >100,000/uL. LVEF>/=50% by MUGA scan or echocardiogram. Serum creatinine <2mg/dL; serum bilirubin<2mg/dL. EXCLUSION: HIV positive. Pregnant women and those of child bearing age who are not using adequate contraception. Prior chemotherapy. Severe pulmonary disease including COPD and asthma. History of prior sensitivity to E.coli derived products.

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Filgrastim + ABVD Chemotherapy<br> | Drug: Filgrastim SD/01<br> <br> * Other names: Neupogen;Drug: Adriamycin<br> <br> * Other names: Adriamycin RDF;Drug: Bleomycin<br> <br> * Other names: BLM;Drug: Vinblastine<br> <br> * Other names: Velban;Drug: DTIC<br> <br> * Other names: Dacarbazine;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Patients with Response to Prophylactic Filgrastim SD/01Chemotherapy |  | Following ABVD chemotherapy course | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hodgkin's lymphoma, Dacarbazine, DTIC, DTIC-Dome, Vinblastine, Velban, Bleomycin sulfate, Blenoxane, BLM, Doxorubicin Hydrochloride, Adriamycin, Filgrastim, G-CSF, Neupogen, Pegfilgrastim, granulocyte colony-stimulating factor
Studying Biomarkers in Samples From Young Patients With Rhabdoid Tumors

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Studying samples of tissue from patients with rhabdoid tumors in the laboratory may help doctor learn more about changes that occur in DNA and identify genes related to cancer. PURPOSE: This research trial studies biomarkers in samples from young patients with rhabdoid tumors.

Detailed Description
-----------------
OBJECTIVES: To investigate the expression and function of transposons in 50 primary rhabdoid tumors. OUTLINE: Freshly frozen rhabdoid tumors will be studied using fluorescence in situ hybridization (FISH) and polymerase chain reaction (PCR) to establish the genomic location of transposons. Protein expression in rhabdoid tumor tissue microarrays is also analyzed.

Official Title
-----------------
Endogenous DNA Transposition in Rhabdoid Tumors

Conditions
-----------------
Kidney Cancer

Intervention / Treatment
-----------------
* Genetic: DNA analysis
* Genetic: fluorescence in situ hybridization
* Genetic: gene expression analysis
* Genetic: gene mapping
* Genetic: microarray analysis
* Genetic: polymerase chain reaction
* Genetic: protein expression analysis
* Other: laboratory biomarker analysis
* Other: medical chart review


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Freshly frozen rhabdoid tumors from either renal or extra-renal sites from children younger than 2 years of age Clinical patient information (age, gender, comorbidities, tumor stage, size, pathology, therapy, outcome) available PATIENT CHARACTERISTICS: Not specified PRIOR CONCURRENT THERAPY: Not specified

Ages Eligible for Study
-----------------
Maximum Age: 1 Year

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Genetic: DNA analysis|nan|
|Genetic: fluorescence in situ hybridization|nan|
|Genetic: gene expression analysis|nan|
|Genetic: gene mapping|nan|
|Genetic: microarray analysis|nan|
|Genetic: polymerase chain reaction|nan|
|Genetic: protein expression analysis|nan|
|Other: laboratory biomarker analysis|nan|
|Other: medical chart review|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Expression and function of transposons in rhabdoid tumors |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
rhabdoid tumor of the kidney